11 results about "Aplastic bone marrow" patented technology

The invention provides an anti-human thrombopoietin antibody AF692, a kit and application of the anti-human thrombopoietin antibody AF692. The anti-human thrombopoietin antibody disclosed by the invention can specifically recognize epitopes without glycosylation modification of natural TPO protein, and has relatively high affinity for recombinant TPO protein and specific epitopes of the recombinant TPO protein. Meanwhile, the anti-human thrombopoietin antibody disclosed by the invention can be used for accurately detecting the content of human thrombopoietin in serum, is not influenced by natural protein glycosylation site heterogeneity, and can be used for accurately identifying and diagnosing early aplastic anemia and primary immune thrombocytopenia; and a more accurate detection method is provided for differential diagnosis of the primary immune thrombocytopenia.

The invention relates to the technical field of hematopoietic reconstruction, in particular to application of costal cartilage derived stem cells and costal cartilage derived stem cells combined with pluripotent progenitor cells, hematopoietic stem cells or cyclosporine in preparation of a preparation for hematopoietic reconstruction. The costal cartilage derived stem cells (CD45-CD51 +) are derived from costal cartilage and have remarkable ecological niche recovery capability. When the cells are used alone or combined with hematopoietic stem cells and pluripotent progenitor cells, the hematopoietic function can be enhanced. The costal cartilage-derived stem cells are directionally differentiated into important supporting cells forming bone marrow ecological niche, secrete hematopoietic cell factors and protect hematopoietic stem / progenitor cells. In treatment of aplastic anemia, costal cartilage-derived stem cells and cyclosporin A have a synergistic effect, and immune-mediated bone marrow failure is improved through dual mechanisms. According to the technical scheme, the technical problem that the effect of treating bone marrow failure and promoting hematopoietic reconstruction by hematopoietic stem cell transplantation is not ideal is solved, and a new way is opened up for treating bone marrow failure and blood system diseases.

The present invention relates to a pharmaceutical composition for treating aplastic anemia containing romiplostim as an active ingredient, which is administered subcutaneously once a week at a dose of 10 μg / kg / week as romiplostim for the first four weeks of administration, and from the fifth week onwards at a dose of more than 10 μg / kg / week up to 20 μg / kg / week as romiplostim.

The invention relates to the technical field of bioinformatics, and provides an analysis method for treating aplastic anemia (AA) targets by cyclosporine, which comprises the following steps: collecting plasma samples from a preliminary diagnosis patient, a disease stable period patient and a healthy control group; the method comprises the following steps: based on a DIA quantitative proteomics method, analyzing proteins in a plasma sample by adopting a liquid chromatography-mass spectrometer (LC-MS) method, and screening differential expression proteins; carrying out enrichment analysis and pathway analysis on the differential expression protein; verifying the expression levels of the differential expression proteins in different groups by adopting an ELISA (Enzyme-Linked Immunosorbent Assay) method to obtain key differential expression proteins; a molecular docking technology is adopted to verify the binding capacity of cyclosporine and the differential expression protein, and the potential of the key differential expression protein as a therapeutic target is determined. Different differential proteins of AA patients and healthy people before and after treatment are successfully obtained, an experimental basis is provided for exploring a mechanism for treating AA by cyclosporine, and possibility is provided for searching a new treatment target.

The invention discloses a traditional Chinese medicine hemagglutination rehabilitation composition for treating aplastic anemia and a preparation method thereof, and is characterized in that the traditional Chinese medicine hemagglutination rehabilitation composition is synthesized from extracts of morinda officinalis, angelica sinensis, American ginseng, rhizoma polygonati, astragalus membranaceus, cistanche, mulberry, raspberry, fructus alpiniae oxyphyllae, hawthorn, Chinese yam, fructus perillae, jujube, semen cassiae and cordyceps sinensis. Compared with the prior art, the traditional Chinese medicine composition for treating aplastic anemia disclosed by the invention has the advantages that a compound compound of a traditional Chinese medicine extract enters blood cells of a human body, mitochondria in the cells converts the compound into ATP (adenosine triphosphate) to supply energy of cell nucleuses (gene DNA), and the cell nucleuses start to split and start and stimulate bone marrow cell regeneration; the traditional Chinese medicine composition can be used for activating body dormant cells, supplementing hemoglobin and recombining stem cells, providing new blood after cell recombination for human body functions, and restarting a basic hematopoietic function of bone marrow, so that the aim of treating aplastic anemia is fulfilled.

The invention provides a composition for treating qi and blood deficiency and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine. The invention discloses a composition for treating qi and blood deficiency. The composition is prepared from the following raw materials: astragalus membranaceus, salvia miltiorrhiza, codonopsis pilosula, fructus lycii, hairyvein agrimony, caulis spatholobi, radix rehmanniae recen, fried malt, fried rhizoma atractylodis macrocephalae, angelica sinensis, fried endothelium corneum gigeriae galli, wine-processed glossy privet fruit, herba epimedii, coptis chinensis, deer-horn glue, tortoise-shell glue and pseudo-ginseng powder. The composition for treating qi and blood deficiency is prepared from a plurality of traditional Chinese medicinal materials with mild properties, not only can tonify yang qi, essence and blood, but also can treat anemia symptoms such as aplastic anemia and the like, myelosuppression caused by platelet, leucopenia and tumor radiotherapy and chemotherapy, and can treat diseases causing qi and blood deficiency. In addition, the invention further provides a preparation method of the composition for treating the qi and blood deficiency, the preparation method of the composition for treating the qi and blood deficiency not only improves the medicine property of the composition for treating the qi and blood deficiency, but also is simple in process, easy to operate and convenient to master.

This application relates to the field of carbon quantum dot traditional Chinese medicine materials, and particularly to the application of human hair carbon in a hematopoietic reagent for aplastic anemia. The application includes: using human hair carbon quantum dots derived from human hair carbon in the preparation of a hematopoietic reagent for chemotherapy-related anemia. This application uses human hair carbon, a traditional Chinese medicine derived from clinical waste, as the core precursor to prepare human hair carbon quantum dots (CrCi-CDs), and applies CrCi-CDs to the development of a hematopoietic reagent for chemotherapy-related anemia. From the raw material source, preparation process, mechanism of action to clinical transformation of the whole chain, it specifically solves the core defects of high raw material cost and unclear biological toxicity risk when existing chemically synthesized carbon dots are used for the treatment of chemotherapy-related anemia, and at the same time meets the clinical drug safety requirements of patients with chemotherapy-induced aplastic anemia.

The invention provides a traditional Chinese medicine composition for treating aplastic anemia. The traditional Chinese medicine composition is prepared from monarch drugs including astragalus membranaceus, prepared rehmannia roots and hairyvein agrimony, ministerial drugs including lychee seeds, rhizoma bletillae and sliced cornu cervi, adjuvant drugs including peach kernels, carthamus tinctorius, lumbricus, rhizoma wenyujin concisum and rabdosia amethystoides, conductant drugs including liquorice and adjuvant drugs including cassia twigs. According to the traditional Chinese medicine composition, the compatibility thought of taking the bulbophyllum and the lychee seeds as the outline is created for the first time, the bletilla striata is combined with the lychee seeds for promoting the circulation of qi, and the antler slices are used for replenishing essence and benefiting marrow, so that a characteristic scheme of regulating qi and blood and dredging and resuscitation is formed. The composition can regulate the core pathogenesis of qi and blood deficiency, marrow sea insufficiency and blood stasis of aplastic anemia at multiple targets, effectively improves the bone marrow hematopoiesis function, solves the problem that the existing therapy is difficult to consider deficiency and excess inclusion, and provides a brand-new and efficient traditional Chinese medicine treatment choice for aplastic anemia.

This invention belongs to the field of animal model technology, specifically relating to a method for constructing an animal model of aplastic anemia and premature ovarian failure (POF) and its application in mesenchymal stem cell therapy. Busulfan and cyclophosphamide were administered intraperitoneally to the animals six times in the following order: first, busulfan was administered three times consecutively, followed by cyclophosphamide three times consecutively, thus establishing an animal model of the dual pathological state of aplastic anemia and POF. Furthermore, based on this animal model, a mesenchymal stem cell therapy based on disease stages was established, achieving significant recovery of ovarian function and providing a reliable technical foundation for clinical translational research on POF in adolescents.

The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and / or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and / or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.

A mouth-nose-ear cavity bleeding emergency treatment device for aplastic anemia patients belongs to the technical field of medical apparatus and instruments, and comprises a hemostasis spray tank, a storage cylinder main body, an adjusting ring, a discharge port and a spray irrigation cover main body, the storage cylinder main body is rotatably connected to the bottom end of the hemostasis spray tank, and a groove is formed in the middle of the bottom of the hemostasis spray tank; when the mouth-nose-ear cavity bleeding emergency treatment device for aplastic anemia patients is used, the ultraviolet disinfection lamp and the disinfection ring in the spray irrigation cover body can disinfect and sterilize the surface of the pressing block, and ultraviolet rays can directly destroy DNA structures of microorganisms such as bacteria and viruses. The pressing device is simple in structure, high in killing rate of pathogenic microorganisms on the surface and in gaps of the pressing block, capable of thoroughly removing residual blood, secretions and other pollutants after use, capable of solving the problem that thorough disinfection is difficult in a traditional cleaning mode, and capable of fundamentally reducing the cross infection risk of aplastic anemia patients caused by pressing device pollution. Moreover, the pressing block can press the disinfected tissues for hemostasis, the probability of continuous bleeding of the patient is reduced, and the spray irrigation cover body made of mirror glass is convenient for the patient to quickly and accurately find bleeding points and stop bleeding.